Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2176081 | 0.80 | CHRNA7 (0.40) | LMNAKCNH2MEN1KMT2ACYP1A2 | |
| SCHEMBL508102 | 0.78 | PYCR1 (0.41) | LMNAKCNH2CYP2A6GSK3BMAOA | |
| SCHEMBL9484463 | 0.78 | LMNA (0.47) | LMNAKCNH2CYP2A6GRM5DRD2 | |
| SCHEMBL16380473 | 0.76 | KCNH2 (0.53) | LMNAKCNH2CYP2A6GRM5MEN1 | |
| SCHEMBL1066892 | 0.76 | KCNH2 (0.53) | LMNAKCNH2CYP2A6GRM5GSK3B | |
| SCHEMBL5079375 | 0.76 | LMNA (0.46) | LMNAKCNH2CYP2A6GRM5DRD2 | |
| SCHEMBL1746428 | 0.76 | LMNA (0.50) | LMNAKCNH2CYP2A6DRD2MEN1 | |
| SCHEMBL2080824 | 0.76 | CYP2C19 (0.60) | LMNAKCNH2CYP2A6GRM5DRD2 | |
| SCHEMBL565489 | 0.76 | APP (0.36) | LMNAKCNH2GSK3BCYP1A2CYP3A4 | |
| SCHEMBL5079648 | 0.76 | LMNA (0.46) | LMNAKCNH2CYP2A6GRM5DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362011-B2 | Tricyclic triazolic compounds | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2013-01-29 | — | — | US | disclosed |
| US-8362011-B2 | Tricyclic triazolic compounds | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2013-01-29 | — | — | US | disclosed |
| EP-2227476-B1 | TRICYCLIC TRIAZOLIC COMPOUNDS | ESTEVE LABOR DR (ES) | 2011-09-07 | — | — | EP | disclosed |
| US-20100298309-A1 | TRICYCLIC TRIAZOLIC COMPOUNDS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2010-11-25 | — | — | US | disclosed |
| US-20100298309-A1 | TRICYCLIC TRIAZOLIC COMPOUNDS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2010-11-25 | — | — | US | disclosed |
| EP-2227476-A1 | TRICYCLIC TRIAZOLIC COMPOUNDS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2010-09-15 | — | — | EP | disclosed |
| EP-2070933-A1 | Tricyclic triazolic compounds | Laboratorios del Dr. Esteve S.A. (ES) | 2009-06-17 | — | — | EP | disclosed |
| WO-2009071657-A1 | TRICYCLIC TRIAZOLIC COMPOUNDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-06-11 | — | — | WO | disclosed |
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-6949661-B2 | 3-substituted-3-(substitutedsulfonyl or sulfanyl) pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase | WYETH HOLDINGS CORPORATION (US) | 2005-09-27 | — | — | US | disclosed |
| EP-0749430-B1 | THIAZOLIDINEDIONE DERIVATIVES AS ANTI-HYPERGLYCEMIC AGENTS | AMERICAN HOME PROD (US) | 1999-08-25 | — | — | EP | disclosed |
| US-5605918-A | SUBSTITUTED THIAZOLIDINE-2,4-DIONES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-02-25 | — | — | US | disclosed |
| EP-0749430-A1 | THIAZOLIDINEDIONE DERIVATIVES AS ANTI-HYPERGLYCEMIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-12-27 | — | — | EP | disclosed |
| US-5574051-A | HYPOGLYCEMIC | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-11-12 | — | — | US | disclosed |
| WO-1995024400-A1 | THIAZOLIDINEDIONE DERIVATIVES AS ANTI-HYPERGLYCEMIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-09-14 | — | — | WO | disclosed |
| EP-0351194-B1 | Thiazole derivatives having a 5-lipoxygenase-inhibiting activity | ICI PLC (GB) | 1994-06-15 | — | — | EP | disclosed |
| US-5196422-A | Antiinflammatory agents, antiallergens | ICI PHARMA (FR) | 1993-03-23 | — | — | US | disclosed |
| US-5089513-A | Antiinflammatory agents; antiallergens; asthma; side effect reduction | ICI PHARMA (FR) | 1992-02-18 | — | — | US | disclosed |
| US-4933367-A | Carboxylic acid derivatives, processes for the preparation thereof, the use thereof, and pharmaceutical compositions which contain these compounds | BOEHRINGER MANNHEIM GMBH (DE) | 1990-06-12 | — | — | US | disclosed |
| EP-0351194-A2 | Thiazole derivatives having a 5-lipoxygenase-inhibiting activity | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298309-A1 | TRICYCLIC TRIAZOLIC COMPOUNDS | SIGMAR1, OPRK1, OPRM1 | LMNA 2305/4885KCNH2 1421/4885CYP2A6 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.